Nurix Therapeutics, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended August 31, 2023, and was signed October 12, 2023. This conflicts with the request metadata identifying the period as 2022 Q3; the filing itself is for 2023 Q3.
Business context
Nurix is a clinical-stage biopharmaceutical company developing medicines that modulate cellular protein levels using its DELigase platform. Its wholly owned clinical programs include BTK degraders NX-2127 and NX-5948 and the CBL-B inhibitor NX-1607. The company has no approved products and has not generated product sales revenue; reported revenue comes from collaborations and licenses.
Financial performance and position
| Metric | Three months ended Aug. 31, 2023 | Nine months ended Aug. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Total revenue | $18.5 million | $61.8 million | $10.8 million; $31.8 million |
| Operating expenses | $58.5 million | $171.6 million | $57.5 million; $167.0 million |
| Loss from operations | $40.0 million | $109.7 million | $46.7 million; $135.2 million |
| Net loss | $37.0 million | $102.0 million | $45.7 million; $133.6 million |
| Basic and diluted net loss per share | $0.68 | $1.88 | $0.90; $2.85 |
Quarterly and year-to-date revenue growth reflected higher collaboration revenue from Gilead and Sanofi; nine-month revenue also included a $20.0 million Gilead license payment. Research and development expense was nearly flat year over year, while general and administrative expense increased. Net losses narrowed, aided by higher collaboration/license revenue and interest income.
At August 31, 2023, cash and cash equivalents were $42.3 million, current marketable securities $216.5 million, and non-current marketable securities $9.9 million—about $268.7 million combined. Total assets were $308.2 million, total liabilities $74.4 million, and stockholders’ equity $233.8 million. The filing reports no debt balance. Current liabilities were $61.5 million, including $32.0 million of current deferred revenue. Accumulated deficit was $503.2 million.
For the nine months, operating cash use was $108.1 million, investing cash inflow was $82.7 million (primarily net marketable-security maturities), and financing cash inflow was $3.2 million. Cash, cash equivalents and restricted cash decreased $22.2 million to $43.2 million. Operating cash use was lower than the $121.9 million used in the comparable 2022 period. Total operating lease commitments were approximately $41.6 million, with $7.6 million expected within 12 months.
Material changes and developments
- For the nine-month period, total revenue rose $30.0 million year over year, including the Gilead license payment; collaboration revenue alone increased $10.0 million.
- Operating expenses increased $4.5 million year to date. Higher personnel, stock-based compensation, clinical and facility costs were partly offset by lower research, preclinical and manufacturing costs.
- In March 2023, Gilead exercised a license option for the first development candidate under its collaboration, generating $20.0 million of license revenue in the first half of fiscal 2023.
- In September 2023, after quarter-end, Nurix entered a collaboration with Seagen. The agreement provides a $60.0 million upfront payment, potential contingent payments of up to approximately $3.4 billion and tiered royalties; Nurix retains U.S. profit-sharing and co-promotion options on two products. These are post-period developments, not August 31 balance-sheet cash.
- Nurix deprioritized DeTIL-0255 after completing the safety run-in of its Phase 1 trial; any expansion was left contingent on a decision about NX-1607’s potential inclusion in future cohorts.
Outlook, risks and contingencies
Management expects existing cash, cash equivalents and marketable securities to fund operations for at least 12 months following issuance of the financial statements. The filing also says these resources will not fund clinical development through commercialization and that substantial additional financing will be required. Future funding needs depend on clinical progress, spending, and collaboration payments; financing may be unavailable or dilutive, and the company may need to reduce or delay programs.
All three lead candidates are in early-stage clinical development. Key risks include clinical failure or delays, uncertain safety and efficacy, patient enrollment, reliance on third-party clinical and manufacturing providers (including single-source suppliers), competition, intellectual-property challenges, and dependence on collaborators to advance partnered programs. Nurix cautions that early or interim clinical results may not predict later outcomes. The company reported no material legal proceedings and no material accrued indemnification liability. It reported disclosure controls and procedures were effective as of August 31, 2023.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the filing is for the quarter ended August 31, 2023, although the request metadata says 2022 Q3.
- Check the timing and cash receipt/accounting treatment of Seagen’s $60.0 million upfront payment, since the agreement was signed after the reporting date.
- Assess the stated 12-month cash runway against the $108.1 million nine-month operating cash use, planned clinical spending and future collaboration receipts.
- Track clinical enrollment, safety and efficacy updates for NX-2127, NX-5948 and NX-1607, and any decision affecting DeTIL-0255.
- Review potential dilution and share overhang: 6.1 million pre-funded warrants remained outstanding at quarter-end, alongside employee equity awards and available issuance capacity under the ATM agreement.